The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Participant blood pressure (both systolic and diastolic)
Timeframe: Baseline
Date of diagnosis of hypertrophic cardiomyopathy
Timeframe: Baseline
Hypertrophic cardiomyopathy genetic testing results
Timeframe: Baseline
Family history of hypertrophic cardiomyopathy
Timeframe: Baseline
Family history of Sudden Cardiac Death (SCD)
Timeframe: Baseline
Participant comorbidities (cardiovascular and non-cardiovascular )
Timeframe: Baseline
Type of prior surgeries and procedures
Timeframe: Baseline and up to week 24
Participant New York Heart Association (NYHA) class category
Timeframe: Baseline, and at weeks 4, 8, 12, 24
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Change in participant New York Heart Association (NYHA) class from baseline
Timeframe: Baseline, and at weeks 4, 8, 12, 24
Duration of mavacamten treatment
Timeframe: Baseline, and at weeks 4, 8, 12, 24
Number of mavacamten dose titrations
Timeframe: Baseline, and at weeks 4, 8, 12, 24
Type of mavacamten dose tritration
Timeframe: Baseline, and at weeks 4, 8, 12, 24
Clinical reason for mavacamten dose titration
Timeframe: Baseline, and at weeks 4, 8, 12, 24
Clinical reason for mavacamten treatment discontinuation
Timeframe: Baseline, and at weeks 4, 8, 12, 24
Left Ventricular Ejection Fraction (LVEF) recovery after mavacamten discontinuation if discontinued due to LVEF<50%,
Timeframe: Baseline, and at weeks 4, 8, 12, 24
Time from mavacamten discontinuation to Left Ventricular Ejection Fraction (LVEF) recovery
Timeframe: Baseline, and at weeks 4, 8, 12, 24
Clinical reason for temporary mavacamten treatment interuption
Timeframe: Baseline, and at weeks 4, 8, 12, 24
Time to temporary mavacamten treatment interruption
Timeframe: Baseline, and at weeks 4, 8, 12, 24
Left Ventricular Ejection Fraction (LVEF) recovery after mavacamten interruption if the interruption was due to LVEF<50%
Timeframe: Baseline, and at weeks 4, 8, 12, 24
Time from mavacamten treatment interruption to Left Ventricular Ejection Fraction (LVEF) recovery
Timeframe: Baseline, and at weeks 4, 8, 12, 24
Time to mavacamten treatment resumption
Timeframe: Baseline, and at weeks 4, 8, 12, 24
Type of hypertrophic cardiomyopathy (HCM) background therapy prescribed
Timeframe: Baseline, and at weeks 4, 8, 12, 24
Type of changes to hypertrophic cardiomyopathy (HCM) background therapy
Timeframe: At baseline, weeks 4, 8, 12, 24